Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSD1235 in Atrial Fibrillation
NCT00281554Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2005
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of vernakalant in Atrial fibrillation (AFib), sponsored by Astellas Pharma. Primary endpoint: Rate of conversion of atrial fibrillation to sinus rhythm for a minimum of 1 minute. Started Oct 2005; status: completed.
02
Drugs
vernakalant
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT00281554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00281554.